Pericellular-acting proteases in human first trimester decidua

Molecular Human Reproduction

Volumn 14, Issue 1, 2008, Pages 41-51

  Plaisier, Margreet ^a,b   Koolwijk, Pieter ^b,c   Willems, Florian ^d   Helmerhorst, Frans M ^a   Van Hinsbergh, Victor W M ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d STIMEZO Plus Clinic   (Netherlands)

Author keywords

Decidua; First trimester; Matrix metalloproteinases; Trophoblast; UNK cells

Indexed keywords

CD56 ANTIGEN; CD68 ANTIGEN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 24; MESSENGER RNA; PROTEINASE; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ADULT; ARTICLE; CELL COUNT; CONTROLLED STUDY; DECIDUA; FEMALE; FIRST TRIMESTER PREGNANCY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; NATURAL KILLER CELL; PATHOPHYSIOLOGY; PREGNANCY TERMINATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUS ABORTION; TROPHOBLAST;

ADULT; ANTIGENS, CD; ANTIGENS, CD56; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; DECIDUA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 20; PEPTIDE HYDROLASES; PREGNANCY; PREGNANCY TRIMESTER, FIRST; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 39449105719     PISSN: 13609947     EISSN: 14602407     Source Type: Journal    
DOI: 10.1093/molehr/gam085     Document Type: Article

References (68)

1. Al-Atrash G, Kitson RP, Xue Y, Mazar AP, Kim MH, Goldfarb RE. uPA and uPAR contribute to NK cell invasion through the extracellular matrix. Anticancer Res 2001;21:1697-1704.
2. Albertsson P, Kim MH, Jonges LE, Kitson RP, Kuppen PJ, Johansson BR, Nannmark U, Goldfarb RH. Matrix metalloproteinases of human NK cells. In Vivo 2000;14:269-276.
3. Alfano D, Franco P, Vocca I, Gambi N, Pisa V, Mancini A, Caputi M, Carriero MV, Iaccarino I, Stoppelli MP. The urokinase plasminogen activator and its receptor: Role in cell growth and apoptosis. Thromb Haemost 2005;93: 205-211.
4. Bai SX, Wang YL, Qin L, Xiao ZJ, Herva R, Piao YS. Dynamic expression of matrix metalloproteinases (MMP-2, -9 and -14) and the tissue inhibitors of MMPs (TIMP-1, -2 and -3) at the implantation site during tubal pregnancy. Reproduction 2005;129:103-113.
5. Bigg HF, Morrison CJ, Butler GS, Bogoyevitch MA, Wang Z, Soloway PD, Overall CM. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res 2001;61 3610-3618.
6. Bjorn SF, Hastrup N, Larsen JF, Lund LR, Pyke C. Messenger RNA for Membrane-type 2 matrix metalloproteinase, MT2-MMP, is expressed in human placenta of first trimester. Placenta 2000;21:170-176.
7. Blasi F, Carmeliet P. uPAR: A versatile signalling orchestrator. Nat Rev. Mol Cell Biol 2002;3:932-943.
8. Blasi F, Vassalli JD, Dano K. Urokinase plasminogen activator: pro-enzyme, receptor and inhibitors. J Cell Biol 1987;104 801-804.
9. Bulmer JN, Lash GE. Human uterine natural killer cells: A reappraisal. Mol Immunol 2005;42:511-521.
10. Bulmer JN, Morrison L, Longfellow M, Ritson A, Pace D. Granulated lymphocytes in human endometrium: Histochemical and immunohistochemical studies Hum Reprod 1991;6:791-798.
11. Burton GJ, Jauniaux E, Watson AL, Maternal connections to the placental intervillous space during the first trimester of human pregnancy: The Boyd collection revisited. Am J Obstet Gynecol 1999;181 718-724.
12. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyante-phenol-chloroform extraction. Anal Biochem 1997;162:156-159.
13. Collen A, Hanemaaijer R, Lupu F, Quax PH, van Lent N, Grimbergen J, Peters E, Koolwijk P, Van Hinsbergh VW. Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood 2003;101:1810-1817.
14. Curry TE, Jr, Osteen KG. The matrix metalloproteinase system: Changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 2003;24:428-465.
15. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-174.
16. Floridon C, Nielsen O, Holund B, Sunde L, Westergaard JG, Thomsen SG, Teisner B. Localization and significance of uPA and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies. Placenta 1999;20:711-721.
17. Galvez BG, Matias-Roman S, Albar JP, Sanchez-Madrid F, Arroyo AG. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J Biol Chem 2001;276:37491-37500.
18. Haller H, Tedesco F, Rukavina D, Radillo O, Gudelj L, Beer AE. Decidual-trophoblast interactions: Decidual lymphoid cell populations in basaland parietal decidua. J Reprod Immunol 1995;28:165-171.
19. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006;12:1065-1074.
20. Hernandez-Barrantes S, Bernardo M, Toth M, Fridman R. Regulation of membrane type-matrix metalloproteinases. Semin Cancer Biol 2002; 12:131-138.
21. van den Heuvel MJ, Chantakru S, Xuemei X, Evans SS, Tekpetey F, Mote PA, Clarke CL, Croy BA. Trafficking of circulating pro-NK cells to the decidualizing uterus: Regulatory mechanisms in the mouse and human. Immunol Invest 2005;34:273-293.
22. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999;5:1135-1142.
23. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularisation by acting as pericellular fibrinolysins. Cell 1998;95:365-377.
24. Hofmann GE, Glatstein I, Schatz F, Heller D, Deligdisch L. Immunohistochemical localization of urokinase-type plasminogen activator and the plasminogen activator inhibitors 1 and 2 in early human implantation sites. Am J Obstet Gynecol 1994;170:671-676.
25. Hotary K, Allen E, Punturieri A, Yana I, Weiss SJ. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol 2000;149:1309-1323.
26. Hotary KB, Yana I, Sabeh F, Li X-Y, Holmbeck K, Birkedal-Hansen H, Allen ED, Hiraoka N, Weiss SJ. Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J Exp Med 2002;195:295-308.
27. Hu ZY, Liu YX, Liu K, Byrne S, Ny T, Feng Q, Ockleford CD. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta. J Anat 1999;194:183-195.
28. Hurskainen T, Seiki M, Apte SS, Syrjakallio-Ylitalo M, Sorsa T, Oikarinen A, Autio-Harmainen H. Production of Membrane-type matrix metalloproteinase 1 (MT-MMP1) in early human placenta: A possible role in placental implantation. J Histochem Cytochem 1998;46 221-229.
29. Khong TY. Immunohistologic study of the leukocytic infiltrate in maternal uterine tissues in normal and preeclamptic pregnancies at term. Am J Reprod Immunol Microbiol. 1987;15:1-8.
30. Kim MH, Kitson RP, Albertsson P, Nannmark U, Basse PH, Kuppen PJ, Hokland ME, Goldfarb RH. Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors. J. Immunol 2000;164:5883-5889.
31. Kindzelskii AL, Amhad I, Keller D, Zhou MJ, Haugland RP, Garni-Wagner BA, Gyetko MR, Todd RF, Petty HR. Pericellular proteolysis by leukocytes and tumor cells on substrates: Focal activation and the role of urokinase-type plasminogen activator. Histochem Cell Biol 2004; 121:299-310.
32. Koolwijk P, van Erck MG, de Vree WJ, Vermeer MA, Weich HA, Hanemaaijer R, Van Hinsbergh VWM. Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996;132:1177-1188.
33. Koolwijk P, Kapiteijn K, Molenaar B, van Spronsen E, Helmerhorst FM, van Hinsbergh VW. Enhanced angiogenic capacity and urokinase-type plasminogen activator expression by endothelial cells isolated from human endometrium. J Clin Endocrinol Metab 2001;86:3359-3367.
34. Kroon ME, Koolwijk P, van Goor H, Weidle UH, Collen A, van der Pluijm G, van Hinsbergh V. Role and localisation of urokinase receptor in the formation of new microvascular structures in fibrin matrices. Am J Pathol 1999;154:1731-1742.
35. Lafleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci 2002;115:3427-3438.
36. Lash GE, Schiessl B, Kirkley M, Innes BA, Cooper A, Searle RF et al Expression of angiogenic growth factors by uterine natural killer cells during early pregnancy. Leukoc Biol 2006;80:572-580.
37. Li XF, Charnock-Jones DS, Zhang E, Hiby S, Malik S, Day K, Licence D, Bowen JM, Gardner L, King A et al. Angiogenic growth factor messenger ribonucleic acids in uterine natural killer cells. J Clin Endocrinol Metab. 2001;86:1823-1834.
38. Llano E, Pendas AM, Freije JP, Nakano A, Knauper V, Murphy G, Lopez-Otin C. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res 1999;59:2570-2576.
39. Multhaupt HA, Mazar A, Cines DB, Warhol MJ, McCrae KR. Expression of urokinase receptors by human trophoblast. A histochemical and ultra-structural analysis. Lab Invest 1994;71:392-400.
40. Nakano M, Hara T, Hayama T, Obara M, Yoshizato K, Ohama K. Membrane-type 1 matrix metalloproteinase is induced in decidual stroma without direct invasion of trophoblast. Mol Hum Reprod 2001;7: 271-277.
41. Nap AW, Dunseiman GA, de Goeij AF, Evers JL, Groothuis PG. Inhibiting MMP activity prevents the development of endometriosis in the chicken chorioallantoic membrane model. Hum Reprod 2004;19: 2180-2187.
42. Nawrocki B, Polette M, Marchand V, Maquoi E, Beorchia A, Tournier JM, Foidart JM, Birembaut P. Membrane-type Matrix metalloproteinase-1 expression at the site of human placentation. Placenta 1996;17 565-572.
43. Pei D. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP. J Biol Chem 1999;274 8925-8932.
44. Pepper MS. Role of matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscl Thromb Vasc Biol 2001;21:1104-1117.
45. Pierleoni C, Samuelsen GB, Graem N, Ronne E, Nielsen BS, Kaufmann P, Castellucci M. Immunohistochemical identification of the receptor for uPA associated with fibrin deposition in normal and ectopic human placenta. Placenta 1998;19:501-508.
46. Plaisier M, Kapiteijn K, Koolwijk P, Fijten C, Hanemaaijer R, Grimbergen JM, Mulder-Stapel A, Quax PH, Helmerhorst FM, van Hinsbergh VW. Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: Role of MT3-MMP. J Clin Endocrinol Metab 2004;89 5828-5836.
47. Plaisier M, Koolwijk P, Hanemaaijer R, Verwey A, Weiden RM, Risse KJ, Jungerius C, Helmerhorst M, Hinsbergh VW. Membrane-type matrix metalloproteinases and vascularisation in human endometrium during the menstrual cycle. Mol Hum Reprod 2006;12:11-18.
48. Plaisier M, Rodrigues S, Willems F, Koolwijk P, van Hinsbergh VW, Helmerhorst FM. Different degree of vascularisation and its relation to the expression of VEGF, PlGF, angiopoietins and their receptors in 1st trimester decidua. Fert Ster 2007;88:176-187.
49. Quenby S, Bates M, Doig T, Brewster J, Lewis-Jones DI, Johnson PM, Vince G. Pre-implantation endometrial leukocytes in women with recurrent miscarriage. Hum Reprod 1999;14:2386-2391.
50. Reuning U, Sperl S, Kopitz C, Kessler H, Kruger A, Schmitt M, Magdolen V. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des 2003;9:1529-1543.
51. Salamonsen LA. Role of proteases in implantation. Rev Reprod 1999;4:11-22.
52. Salamonsen LA, Dimitriadis E, Jones RL, Nie G. Complex regulation of decidualisation: A role for cytokines and proteases - a review. Placenta 2003;24:S76-S85.
53. Seiki M, Yana I. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 2003;94:569-574.
54. Sindram-Trujillo AP, Scherjon SA, van Hulst-van Miert PP, van Schip JJ, Kanhai HH, Roelen DL, Claas FH. Differential distribution of NK cells in decidua basalis compared with decidua parietalis after un-complicated human term pregnancy. Hum Immunol 2003;64:921-929.
55. Solberg H, Rinkenberger J, Danà K, Werb Z, Lund LR. A functional overlap of plasminogen and MMPs regulates vascularization during placental development. Development. 2003;130:4439-4450.
56. Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, Gilles C, Deroanne C, Thompson EW, Foidart JM, Noel A. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 2002;16:555-564.
57. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001;158:419-429.
58. Spengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69: 381-387.
59. Stetler-Stevenson W. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J Clin Invest 1999;103: 1237-1241.
60. Tanaka SS, Togooka Y, Sato H, Seiki M, Tojo H, Tachi C. Expression and localisation of membrane type matrix metalloproteinase-1 (MT1-MMP) in trophoblast cells of cultured mouse blastocysts and ectoplacental cones. Placenta 1998;19:41-48.
61. Tuckerman E, Laird SM, Prakash A, Li TC. Prognostic value of the measurement of uterine natural killer cells in the endometrium of women with recurrent miscarriage. Hum Reprod 2007;22:2208-2213.
62. Vailhe B, Dietl J, Kapp M, Toth B, Arck P. Increased blood vessel density in decidua parietalis is associated with spontaneous human first trimester abortion. Hum Reprod 1999;14:1628-1634.
63. Van Boheemen PA, Van den Hoogen CM, Koolwijk P. Comparison of the inhibition of urokinase-type plasminogen activator (u-PA) activity by monoclonal antibodies specific for u-PA as assesed by different assays. Fibrinolysis 1995;9:343-349.
64. Van Hinsbergh VWM, Engelse MA, Quax PHA. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscl Thromb Vasc Biol 2006;26:716-728.
65. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003;92:827-839.
66. Vuorela P, Carpen O, Tulppala M, Halmesmaki E. VEGF, its receptors and the tie receptors in recurrent miscarriage. Mol Hum Reprod 2000; 6: 276-282.
67. Yagel S, Geva TE, Solomon H, Shimonovitz S, Reich R, Finci-Yeheskel Z, Mayer M, Milwidsky A. High levels of human chorionic gonadotropin retard first trimester trophoblast invasion in vitro by decreasing urokinase plasminogen activator and collagenase activities. J Clin Endocrinol Metab 1993;77:1506-1511.
68. Zygmunt M, Herr F, Munstedt K, Lang U, Liang OD. Angiogenesis and vasculogenesis in pregnancy. Eur J Obstet Gynecol Reprod Biol 2003;110:S10-S18.